UNSPSC 51101670: Moxidectin

This classification denotes an antiparasitic agent with the molecular formula C37H53NO8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NGU5H31YO9, chemically known as milbemycin b, 5-o-demethyl-28-deoxy-25-((1e)-1,3-dimethyl-1-butenyl)-6,28-epoxy-23-(methoxyimino)-, (6r,23e,25s)- but generally known as moxidectin, which bears US NIH Compound Identifier 9571036. European Medicines Agency schedules Moxidectin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09085MIG.

UNSPSC 51101670 Moxidectin is a Commodity code for veterinary antiparasitic pharmaceuticals, yet the recent state and local opportunities tagged under it do not reflect purchases of moxidectin itself. Instead, the code shows activity in broader pharmaceutical procurement — specifically emergency-response and public-health drugs such as naloxone, ciprofloxacin, and doxycycline. State and local issuing bodies using this code include health departments and county public-health agencies acquiring pharmaceutical products through piggyback contracts and competitive bidding processes. The scope of work reflects pharmaceutical warehouse supply and distribution, with contracts structured around fixed-price warehouse orders or annual unit-based purchases with quarterly or periodic delivery cycles.

The Seminole County, Florida Invitation for Bid (IFB) posted June 30, 2026 sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2026 response deadline and potential FEMA funding. The Illinois Department of Public Health awarded a pharmaceutical piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 for doxycycline hyclate and ciprofloxacin hydrochloride with a total contract value of $2,999,999.11 over twelve months plus renewal options. Recent activity appears concentrated in Florida and Illinois, though the mismatch between the code's nominal scope and actual pharmaceutical procurement suggests either a cataloging error in the underlying jurisdictional systems or a broader interpretation of antiparasitic pharmaceutical codes to encompass emergency-response drugs in state and local public-health procurement.